The company had logged a PAT of Rs 193 crore in January-March 2021-22.
Mankind Pharma on Wednesday reported 52 per cent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales.
For the full year ended March 31, 2023, the company's revenue from operations stood at INR 8,749 crore, up by 12% YoY and EBITDA reached INR 1,913 crore with a margin of 21.9%.
The company had logged a PAT of Rs 193 crore in January-March 2021-22. The company’s net profit stood at ₹1,310 Cr during 12MFY23 down by 10% from ₹1,453 Cr in 12MFY22.
Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement.
In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year.
The company maintained its strong growth trajectory during the year..our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories.
Earlier this month, the Income Tax Department conducted raids on the premises of the company over allegations of tax evasion.
Mankind Pharma Q4FY23 results are very good with strong YoY sales growth but the stock price has strong resistance at 1385 on the Daily charts.